5 November 2020 – The operating landscape has changed remarkably for many life science and technology businesses in the Cambridge Cluster since the March 23 lockdown and subsequent restrictions affecting lifestyle and working practices.
https://www.alchemab.com/wp-content/uploads/2020/03/Alchemab-logo.png00resiliencehttps://www.alchemab.com/wp-content/uploads/2020/03/Alchemab-logo.pngresilience2020-11-05 09:00:472020-12-07 10:48:49Casting a spell: The Killer50 Magic Circle is unveiled
1 November 2020 – The UK BIA Antibody Taskforce, a UK consortium developing antibodies for treating COVID-19, has reached a major milestone – the identification of differentiated antibody combinations that will be taken forward for further development as an antibody cocktail.
29 October 2020 – The UK BIA Antibody Taskforce, a leading UK consortium developing antibodies for treating COVID-19 has reached a major milestone – the identification of differentiated antibody combinations that will be taken forward for further development as an antibody “cocktail”. The Taskforce developed an accelerated and rigorous multifaceted approach to create a pool of over 600 novel candidates and identified a set of antibodies with the greatest potential.
https://www.alchemab.com/wp-content/uploads/2020/03/Alchemab-logo.png00resiliencehttps://www.alchemab.com/wp-content/uploads/2020/03/Alchemab-logo.pngresilience2020-10-29 15:16:332020-12-07 10:49:55Novel COVID-19 Antibody Therapy Candidates Identified by Leading UK Biotech Consortium
29 September 2020 – Alchemab, a UK biotech company focused on harnessing the power of adaptive immune systems to cure disease, announced a strategic partnership with the Alberta Machine Intelligence Institute (Amii) to accelerate its adoption of artificial intelligence.
https://www.alchemab.com/wp-content/uploads/2020/03/Alchemab-logo.png00resiliencehttps://www.alchemab.com/wp-content/uploads/2020/03/Alchemab-logo.pngresilience2020-09-29 09:00:142020-11-26 10:12:00UK-based Alchemab partners with Amii to accelerate the development of novel therapeutics to cure disease
16 July 2020 – Three companies at Oxford’s BioEscalator are developing new detection methods and have discovered potential therapeutics in the fight against COVID-19. Even before the lockdown began, Nucleome Therapeutics, Alchemab Therapeutics and Hutano Diagnostics all quickly redirected their scientific expertise and business plans. These rapid innovations were achieved through collaborations with nearby experts, highlighting the importance of knowledge sharing in solving urgent healthcare problems.
23 June 2020 – Two Cambridge companies fly the flag for the UK cluster in the first global cohort of Illumina’s genomics accelerator. Alchemab Therapeutics and Tailor Bio are among three companies that comprise the inaugural funding cycle of Illumina Accelerator Cambridge UK.
https://www.alchemab.com/wp-content/uploads/2020/03/Alchemab-logo.png00resiliencehttps://www.alchemab.com/wp-content/uploads/2020/03/Alchemab-logo.pngresilience2020-06-23 09:00:582020-11-26 10:22:55Illumina unveils first Cambridge cohort for global genomics accelerator
23 June 2020 – Illumina, Inc. has selected seven early-stage companies to join the first global cohort of Illumina Accelerator, the company creation engine focused on partnering with entrepreneurs to build breakthrough genomics startups.
https://www.alchemab.com/wp-content/uploads/2020/03/Alchemab-logo.png00resiliencehttps://www.alchemab.com/wp-content/uploads/2020/03/Alchemab-logo.pngresilience2020-06-23 09:00:302020-11-26 10:24:54Illumina Accelerator Welcomes First Global Cohort of Genomics Startups
4 June 2020 – A novel Cambridge UK life science startup – Alchemab Therapeutics – looks set for global glory by identifying and harnessing the power of naturally protective antibodies to combat a broad range of hard-to-treat diseases.
https://www.alchemab.com/wp-content/uploads/2020/03/Alchemab-logo.png00resiliencehttps://www.alchemab.com/wp-content/uploads/2020/03/Alchemab-logo.pngresilience2020-06-04 09:00:512020-11-26 10:21:46Alchemab: One for the future and another first for Cambridge
1 May 2020 – Crisis is the mother of invention and COVID-19 is no exception. But amid all the gloom are signs of a nascent revolution in how we create and develop new drugs, vaccines and diagnostics. The U.K. life sciences industry is rising to the challenge with a mix of collaboration, speed, creativity and resource commitment, to capitalize on the science and technology it has invested in over the last few years.
https://www.alchemab.com/wp-content/uploads/2020/03/Alchemab-logo.png00resiliencehttps://www.alchemab.com/wp-content/uploads/2020/03/Alchemab-logo.pngresilience2020-05-01 09:00:112020-11-26 10:26:17How the U.K. healthcare sector is leveraging its strengths to beat COVID-19
55-56 Russell Square
Meditrina Building 260
Babraham Research Campus